Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera

NEW YORK, April 4, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Arrowhead Research Corp. Analyst Notes 

On April 1, 2014, Arrowhead Research Corp. (Arrowhead) announced that it has successfully completed enrollment of 8 patients in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. "The pace of patient accrual for the ARC-520 Phase 2a study has been very encouraging with the first dose group being enrolled and dosed in just over a week," said Christopher Anzalone, Ph.D., Arrowhead's President and CEO. "According to the study protocol, we expect to begin dosing the next cohort in May and remain confident that we can release top line data in the third quarter. ARC-520 has the potential to be the first drug candidate ever to demonstrate consistent hepatitis B surface antigen reduction in humans, which is thought to be critical in achieving a functional cure for chronic HBV." The full analyst notes on Arrowhead Research Corp. are available to download free of charge at:

http://www.AnalystsReview.com/04042014/ARWR/report.pdf

--

Providence Service Corp. Analyst Notes 

On March 31, 2014, Providence Service Corp. (Providence) announced that it has entered into an agreement to acquire Ingeus Limited (Ingeus). According to the Company, under the terms of the agreement, Providence will acquire 100% of Ingeus for £35 million or $58 million in cash. Providence's CEO, Warren Rustand commented, "Ingeus complements our existing businesses, both strategically and culturally, and shares our core values, focus on integrity, and commitment to customer-centered care through innovation. Importantly, because there is no overlap of current clients, there will be significant opportunity for sharing of expertise." The full analyst notes on Providence Service Corp. are available to download free of charge at:

http://www.AnalystsReview.com/04042014/PRSC/report.pdf

--

Durata Therapeutics, Inc. Analyst Notes 

On March 31, 2014, Durata Therapeutics Inc. (Durata) announced that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee voted 12 to 0 that the Company has provided substantial evidence of the safety and effectiveness of its investigational drug, Dalvance^[TM] (dalbavancin) for injection. According to the Company, Dalvance^[TM] for injection is meant for the treatment of adult patients with acute bacterial skin and skin structure infections, caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. Paul R. Edick, Durata's CEO commented, "We are pleased with the positive outcome of today's Advisory Committee meeting, and the confidence that was expressed regarding the safety and effectiveness of Dalvance. If approved by the FDA, Dalvance would be the first once-weekly antibiotic for ABSSSI, providing an alternative to current once- or twice-daily treatments." The full analyst notes on Durata Therapeutics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04042014/DRTX/report.pdf

--

Orthofix International N.V. Analyst Notes 

On March 27, 2014, Orthofix International N.V. (Orthofix) reported its Q4 2013 and full-year 2013 financial results. For the quarter, net sales were $106.1 million, down 9.6% YoY. Net loss from continuing operations was $9.3 million in Q4 2013, compared to a net income of $16.0 million in Q4 2012. For full year 2013, net sales totaled $400.5 million, down 10.5% YoY. Net loss from continuing operations was $15.7 million in full year 2013, compared to a net income of $45.1 million in full year 2012. Orthofix's President and CEO, Brad Mason commented, "This past year has been challenging and the 2013 financial performance is not reflective of where the Company should be operating. However, we expect stronger financial results in 2014 and are laying the groundwork for further growth and profitability in 2015 and 2016. We are confident that the changes we have made and the initiatives currently underway are resulting in a stronger Company driven by integrity and with a renewed focus on delivering results that meet or exceed our stakeholders' expectations." The full analyst notes on Orthofix International N.V. are available to download free of charge at:

http://www.AnalystsReview.com/04042014/OFIX/report.pdf

--

Idera Pharmaceuticals, Inc. Analyst Notes  

On March 28, 2014, Idera Pharmaceuticals, Inc. (Idera) announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The Company informed that the trial met its primary objective to evaluate the safety and tolerability of IMO-8400 over a 12-week treatment period, as well as its secondary objective of demonstrating clinical activity in patients with psoriasis as assessed by Psoriasis Area and Severity Index (PASI). Sudhir Agrawal, D. Phil., CEO of Idera, commented. "With these data, we can now pursue our announced business strategy and advance our TLR antagonist drug candidates for the treatment of orphan diseases with high unmet medical need. Towards this goal, our clinical development strategy for IMO-8400 is focused on B-cell lymphomas harboring the MYD88 L265P mutation, and on orphan autoimmune disease indications." The full analyst notes on Idera Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04042014/IDRA/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED